NASDAQ · WENAW
Anew Medical, Inc.
Healthcare · Biotechnology
$0.04
Down-$0.00 (-0.25%)
Updated Aug 16, 2026, 4:00 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 681.44K
- P/E ratio
- 5.26
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 4K
- Avg. volume
- 0
Price performance
WENAW price history
1M range · 0 trading sessions · Daily adjusted prices
WENAW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest WENAW news
The latest Smart Investors Daily articles mentioning WENAW.
Stock researchCompany · Overview
WENAW research
Overview
Company profile and research snapshot.
Company profile
Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
